Phase II, Multi-Center, Open-Label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-Line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas.

Trial Profile

Phase II, Multi-Center, Open-Label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-Line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2014

At a glance

  • Drugs Gemcitabine (Primary) ; Panitumumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms APPRISE 1
  • Sponsors Amgen
  • Most Recent Events

    • 11 Mar 2010 Actual patient number is 3 as reported by ClinicalTrials.gov.
    • 11 Mar 2010 Actual end date (1 Apr 2009) added as reported by ClinicalTrials.gov.
    • 29 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top